Skip to main content
. Author manuscript; available in PMC: 2014 May 27.
Published in final edited form as: Cancer Gene Ther. 2014 Jan 17;21(1):38–44. doi: 10.1038/cgt.2013.81

Figure 3.

Figure 3

Depletion of myeloid-derived suppressor cells (MDSCs) by systemic delivery of Gr1 antibody does not alter the effects of intracranial interleukin-12 (IL-12) immunotherapy. (a) MDSC depletion does not affect the survival of animals treated with IL-12 gene therapy. One week after establishing GL261-OVA tumors, mice were injected intracranially with phosphate-buffered saline (PBS), Ad.GFP or Ad.mIL12 with or without MDSC depletion. (b) The effect of Gr1-Ab depletion on induction of CD8 T-cell recruitment in the brain (i) and quantification of immune memory response to OVA in intracranial CD8 T cells (ii). Immune cells from animals bearing orthotopic GL261-OVA glioma and treated with IL-12 in the presence or absence of MDSC depletion were segregated from whole brain homogenate via a Percoll gradient and stimulated as shown in the figure with either control (Sc peptide) or OVA peptide in the presence of costimulatory signals from CD28/CD49b antibodies. Interferon-γ (IFN-γ) induction was quantified by flow cytometry. ND, none detected; NS, nonsignificant difference; *P<0.05.